ARHGEF3 and non-small cell lung carcinoma: In this study, we found that ARHGEF3 was a new regulator of ACLY in non-small cell lung cancer, which stabilized ACLY by reducing its acetylation and decreasing its ubiquitination, thus promoting tumor growth and progression.